|
1
|
Packer M: Sudden unexpected death in
patients with congestive heart failure: A second frontier.
Circulation. 72:681–685. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jongsma HJ and Wilders R: Gap junctions in
cardiovascular disease. Circ Res. 86:1193–1197. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saffitz JE, Davis LM, Darrow BJ, Kanter
HL, Laing JG and Beyer EC: The molecular basis of anisotropy: Role
of gap junctions. J Cardiovasc Electrophysiol. 6:498–510. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dupont E, Matsushita T, Kaba RA, Vozzi C,
Coppen SR, Khan N, Kaprielian R, Yacoub MH and Severs NJ: Altered
connexin expression in human congestive heart failure. J Mol Cell
Cardiol. 33:359–371. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kostin S, Rieger M, Dammer S, Hein S,
Richter M, Klovekorn WP, Bauer EP and Schaper J: Gap junction
remodeling and altered connexin43 expression in the failing human
heart. Mol Cell Biochem. 242:135–144. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang X and Gerdes AM: Chronic pressure
overload cardiac hypertrophy and failure in guinea pigs: III.
Intercalated disc remodeling. J Mol Cell Cardiol. 31:333–343. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sepp R, Severs NJ and Gourdie RG: Altered
patterns of cardiac intercellular junction distribution in
hypertrophic cardiomyopathy. Heart. 76:412–417. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Severs NJ, Coppen SR, Dupont E, Yeh HI, Ko
YS and Matsushita T: Gap junction alterations in human cardiac
disease. Cardiovasc Res. 62:368–377. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kitamura H, Ohnishi Y, Yoshida A, Okajima
K, Azumi H, Ishida A, Galeano EJ, Kubo S, Hayashi Y, Itoh H and
Yokoyama M: Heterogeneous loss of connexin43 protein in nonischemic
dilated cardiomyopathy with ventricular tachycardia. J Cardiovasc
Electrophysiol. 13:865–870. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hahn AF, Ainsworth PJ, Naus CC, Mao J and
Bolton CF: Clinical and pathological observations in men lacking
the gap junction protein connexin 32. Muscle Nerve Suppl. 9(Suppl):
S39–S48. 2000. View Article : Google Scholar
|
|
11
|
Gutstein DE, Liu FY, Meyers MB, Choo A and
Fishman GI: The organization of adherens junctions and desmosomes
at the cardiac intercalated disc is independent of gap junctions. J
Cell Sci. 116:875–885. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Patel VV, Kostetskii I, Xiong Y, Chu
AF, Jacobson JT, Yu C, Morley GE, Molkentin JD and Radice GL:
Cardiac-specific loss of N-cadherin leads to alteration in
connexins with conduction slowing and arrhythmogenesis. Circ Res.
97:474–481. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sanford JL, Edwards JD, Mays TA, Gong B,
Merriam AP and Rafael-Fortney JA: Claudin-5 localizes to the
lateral membranes of cardiomyocytes and is altered in
utrophin/dystrophin-deficient cardiomyopathic mice. J Mol Cell
Cardiol. 38:323–332. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Toyofuku T, Yabuki M, Otsu K, Kuzuya T,
Hori M and Tada M: Direct association of the gap junction protein
connexin-43 with ZO-1 in cardiac myocytes. J Biol Chem.
273:12725–12731. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hunter AW, Barker RJ, Zhu C and Gourdie
RG: Zonula occludens-1 alters connexin43 gap junction size and
organization by influencing channel accretion. Mol Biol Cell.
16:5686–5698. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hunter AW, Jourdan J and Gourdie RG:
Fusion of GFP to the carboxyl terminus of connexin43 increases gap
junction size in HeLa cells. Cell Commun Adhes. 10:211–214. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin C, Martyn KD, Kurata WE, Warn-Cramer
BJ and Lau AF: Connexin43 PDZ2 binding domain mutants create
functional gap junctions and exhibit altered phosphorylation. Cell
Commun Adhes. 11:67–87. 2004. View Article : Google Scholar
|
|
18
|
Bruce AF, Rothery S, Dupont E and Severs
NJ: Gap junction remodelling in human heart failure is associated
with increased interaction of connexin43 with ZO-1. Cardiovasc Res.
77:757–765. 2008. View Article : Google Scholar
|
|
19
|
Laing JG, Saffitz JE, Steinberg TH and
Yamada KA: Diminished zonula occludens-1 expression in the failing
human heart. Cardiovasc Pathol. 16:159–164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laing JG, Tadros PN, Westphale EM and
Beyer EC: Degradation of connexin43 gap junctions involves both the
proteasome and the lysosome. Exp Cell Res. 236:482–492. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leithe E and Rivedal E: Epidermal growth
factor regulates ubiquitination, internalization and
proteasome-dependent degradation of connexin43. J Cell Sci.
117:1211–1220. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Musil LS, Le AC, VanSlyke JK and Roberts
LM: Regulation of connexin degradation as a mechanism to increase
gap junction assembly and function. J Biol Chem. 275:25207–25215.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berthoud VM, Tadros PN and Beyer EC:
Connexin and gap junction degradation. Methods. 20:180–187. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Girao H and Pereira P: The proteasome
regulates the interaction between Cx43 and ZO-1. J Cell Biochem.
102:719–728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Leithe E and Rivedal E: Ubiquitination and
down-regulation of gap junction protein connexin-43 in response to
12-O-tetradecanoylphorbol 13-acetate treatment. J Biol Chem.
279:50089–50096. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Borer JS, Jason M, Devereux RB, Fisher J,
Green MV, Bacharach SL, Pickering T and Laragh JH: Function of the
hypertrophied left ventricle at rest and during exercise.
Hypertension and aortic stenosis. Am J Med. 75:34–39. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mettler FP, Young DM and Ward JM:
Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive
heart failure) in rats. Cancer Res. 37:2705–2713. 1977.PubMed/NCBI
|
|
28
|
Rabelo E, De Angelis K, Bock P, Gatelli
Fernandes T, Cervo F, Bellό Klein A, Clausell N and Cláudia
Irigoyen M: Baroreflex sensitivity and oxidative stress in
adriamycin-induced heart failure. Hypertension. 38:576–580. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Singal PK, Iliskovic N, Li T and Kumar D:
Adriamycin cardiomyopathy: Pathophysiology and prevention. Faseb J.
11:931–936. 1997.PubMed/NCBI
|
|
30
|
Depre C, Wang Q, Yan L, Hedhli N, Peter P,
Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, et al:
Activation of the cardiac proteasome during pressure overload
promotes ventricular hypertrophy. Circulation. 114:1821–1828. 2006.
View Article : Google Scholar : PubMed/NCBI
|
